HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance66% confidence

Rare Disease Drug Approvals

Source: FDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (rare disease) as Casper Pharma; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

This page describes recent rare disease drug approvals that received CDER or FDA communication. This is not an exhaustive list of all rare disease drug approvals.

Supporting Context

Therapeutic area
Rare Diseases · Cystinosis
Sub-indication
Rare Disease

Related signal: FDA Accepts NDA for Tiocystin by Casper Pharma

Source

View source document

Related Signal

Open signal — FDA Accepts NDA for Tiocystin by Casper Pharma
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.